ARTICLE | Clinical News
APD403: Phase IIa data
October 8, 2012 7:00 AM UTC
Top-line data from a Danish and U.K. Phase IIa trial in 51 cancer patients receiving chemotherapy showed that APD403 plus ondandetron produced a complete response, defined as no vomiting and no anti-e...